电邮这篇文章 Palmarplantar erythrodysesthesia in the patients with oncological pathology treated with multikinase inhibitors and the method for its correction
- 作者: Kruglova L.S1, Shatokhina E.A.2,1, Kotenko K.V2
-
隶属关系:
- State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department
- Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation
- 期: 卷 15, 编号 6 (2016)
- 页面: 314-317
- 栏目: Articles
- URL: https://journal-vniispk.ru/1681-3456/article/view/41627
- DOI: https://doi.org/10.18821/1681-3456-2016-15-6-314-317
- ID: 41627
如何引用文章
全文:
详细
Introduction. The modern anti-tumour preparations from the group of multikinase inhibitors exhibit the high clinical effectiveness. Courses of therapy with such medications are indispensable and vitally important for the treatment of the patients presenting with oncological pathology but, unfortunately, happen to give rise to the development of a toxic reaction in the form of рalmar-plantar erythrodysesthesia which not infrequently prevents the completion of the full-scale treatment. The determination of the adequate skin condition is an indispensable component of the combined treatment of the oncological patients. Materials and methods. The present study included 9 patients treated with various preparations from the group of multikinase inhibitors. All of them developed toxic cutaneous reactions in the form of grade II-III palmar-plantar erythrodysesthesia which was corrected with the use of thioctic acid-based preparation at a daily dose of 600 mg given during 14 days in the combination with pharmaphoresis of the cream containing 0.1% of betamethasone valerate. Results. The use of the proposed therapeutic modality resulted in the reduction of the severity of the clinical manifestations of palmar-plantar erythrodysesthesia, such as erythema, infiltration, desquamation, fissures, etc. Simultaneously, the treatment eliminated certain subjective symptoms including pruritus, pain, and paresthesia. Taken together, these effects significantly improved the patients’ condition and allowed the course of antitumour therapy to be totally completed. Conclusion. The patients presenting with palmar-plantar erythrodysesthesia should be managed with the use of multikinase inhibitors in the combination with the oral administration of a thioctic acid-based preparation and local pharmaphoresis of the cream containing 0.1% of betamethasone valerate.
作者简介
L. Kruglova
State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department123104, Moscow, Russian Federation
Evgeniya Shatokhina
Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation; State budgetary healthcare institution of Moscow “Moscow scientific-practical center of dermatovenereology and cosmetology”, Moscow Healthcare Department
Email: e.a.shatokhina@gmail.com
candidate med. sci., associated professor for the Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the Russian Federation 121359, Moscow, Russian Federation
K. Kotenko
Federal state budgetary institution of additional professional education “Central State Medical Academy”, Presidential Administration of the President of Russian Federation121359, Moscow, Russian Federation
参考
- Johnston J.B., Navaratnam S., Pitz M.W. et al. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 2006; 13: 3483-92.
- Heidary N., Naik H., Burgin S. Chemotherapeutic agents and the skin: an update. J. Am. Acad. Dermatol. 2008; 58: 545-70.
- Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 2009; 6(8): 465-77.
- Chu D., Fillos T., Wu S. Risk of handfoot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol. 2008; 47: 176-86.
- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat. Rev. 2005; 31(6): 456-73.
- Lacouture M.E., Reilly L.M., Gerami P., Guitart J. Hand-foot skin reaction in cancer patients treated with the multikinase inhibitor sorafenib and sunitinib. Ann. Oncol. 2008; 19: 1955-61.
- Robert C., Mateus C., Spatz A., Wechsler J., Escudier B. Dermatologic symptoms associated with the multikinaseinhibitor sorafenib. J. Am. Acad. Dermatol. 2009; 60: 299-305.
- Degen A., Alter M., Schenck F., Satzger I., Völker R., Kapp A., Gutzmer A. Hand-Foot Syndrome in cancer patients: concepts, assessment and management of symptoms. JDDG. 2010; 8: 652-61.
- Jayastu S., Anup J.D., Abhijeet G., Leni G., Auro V. Sorafenib induced hand foot skin rash in FLT3 ITD mutated acute myeloid leukemia-A. Mediterr. J. Hematol. Infect. Dis. 2014; 6(1): e2014016.
- Lacouture M.E., Wu S., Robert C. et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008; 13: 1001-11.
- Robert C., Soria J.C., Spatz A. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6: 491-500.
- Gurer H., Ozgunes H., Oztezcan S. et al. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic. Biol. Med. 1999; 27(1-2): 75-81.
补充文件
